NOVARTIS' generic/biosimilar arm Sandoz has confirmed that the US Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application for fluticasone propionate/salmeterol combination product, a substitutable generic version of Advair Diskus which is marketed in Australia by GlaxoSmithKline Australia as Seretide.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 17
